Wednesday, March 25, 2020

GILD Seeks To Revoke Coveted Status, ELOX Pauses Trial, PRQR On Watch

Today's Daily Dose brings you news about Immutep's breast cancer trial results, ProQR Therapeutics' near-term catalyst, Eloxx Pharma pausing patient enrolment in its cystic fibrosis trial due to COVID-19 pandemic, Jazz Pharma's regulatory catalyst and Gilead seeking to revoke the coveted status for potential COVID-19 drug.

from RTT - Biotech https://ift.tt/2ycOkVD
via IFTTT

No comments:

Post a Comment